Dysregulation of cMet signaling–mediated proliferation, apoptosis, and migration through cMet overexpression, MET amplification, MET mutation, or HGF‐induced activation has been widely demonstrated in oncogenic processes across multiple tumor types, including NSCLC (Smyth et al, 2014; Tsuta et al, 2012; Van Der Steen et al, 2015). The gene discussed is MET; the disease is neoplasm.